Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

David Gonzales

Physician Assistant Fort Worth, TX Physician Assistant

NPI 1588766919 CMS profile 298548

4201 Camp Bowie Blvd, Fort Worth, TX 76107

Open in the dashboard

General payments

$12,826

376 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Gonzales of Fort Worth, TX is reported in the CMS Open Payments database as having received $12,826 across 376 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,272 110
2024 General $2,482 81
2023 General $1,162 39
2022 General $2,655 65
2021 General $3,254 81

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Gonzales
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to David Gonzales were reported at $3,272. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year David Gonzales Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $3,254 $132 $37–$438 $132
2022 $2,655 $155 $48–$522 $149
2023 $1,162 $167 $52–$557 $160
2024 $2,482 $178 $55–$600 $164
2025 $3,272 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Biohaven Pharmaceuticals, Inc. $1,429 14 payments
  2. Boston Scientific Corporation $1,408 13 payments
  3. AbbVie, Inc. $1,179 55 payments
  4. Lilly USA, LLC $1,039 29 payments
  5. Novo Nordisk Inc $980 28 payments
  6. Pfizer Inc. $687 42 payments
  7. Abbott Laboratories $686 9 payments
  8. AstraZeneca Pharmaceuticals LP $577 17 payments
  9. GlaxoSmithKline, LLC. $567 28 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $486 9 payments
  11. Other $3,788 132 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,628 370 payments
  2. Consulting Fee $1,200 1 payment
  3. Travel and Lodging $966 4 payments
  4. Education $32 1 payment
Products named General payments · program years 2021–2025
  1. NURTEC ODT Primary Care $1,709 24 payments
  2. Spectra WaveWriter $1,206 7 payments
  3. FreeStyle Libre 3 $631 6 payments
  4. JARDIANCE $600 13 payments
  5. UBRELVY $540 27 payments
  6. NURTEC ODT Pain $538 39 payments
  7. Wegovy $537 7 payments
  8. Kerendia $486 9 payments
  9. RYBELSUS $334 14 payments
  10. ZEPBOUND $278 7 payments
  11. Other $6,605 269 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 74 drugs

Part D claims

2,631

Median for Physician Assistant: 241

Drug cost

$328,489

Median for Physician Assistant: $4,110

Branded share of claims

21.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 79 $81,653
Jardiance Empagliflozin Brand 53 $57,168
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 45 $31,238
Linzess Linaclotide Brand 28 $26,318
Mounjaro Tirzepatide Brand 18 $21,635
Tradjenta Linagliptin Brand 18 $19,976
Xarelto Rivaroxaban Brand 23 $19,627
Eliquis Apixaban Brand 23 $18,593
Januvia Sitagliptin Phosphate Brand 19 $15,476
Trulicity Dulaglutide Brand 11 $10,717

The 10 drugs with the highest cost, of 74 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$18,962

Of which drugs: $2,159

Medicare patients

98

Average age 74

Services billed

447

52 women, 46 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 39%
Diabetes 37%
Chronic kidney disease 37%
Ischemic heart disease 23%
Depression 23%
COPD 17%
Cancer 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 15 15 $1,227

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Lilly USA, LLC $301
  • Boehringer Ingelheim Pharmaceuticals, Inc. $186
$488 53 —
BOTOX
  • AbbVie, Inc. $137
$137 — —
SHINGRIX
  • GlaxoSmithKline, LLC. $128
$128 — —
Repatha
  • Amgen Inc. $125
$125 — —
Wegovy
  • Novo Nordisk Inc $122
$122 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

376 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record